3-硝基-4-(1-吡咯烷)苯甲醛 | 39911-29-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-硝基-4-(1-吡咯烷)苯甲醛
• 中文别名: 3-硝基-4-哌啶苯甲醛
• 英文名称: 3-nitro-4-(piperidin-1-yl)benzaldehyde
• 英文别名: 3-nitro-4-piperidin-1-ylbenzaldehyde
• CAS: 39911-29-0
• 化学式: C₁₂H₁₄N₂O₃
• mdl: MFCD00831780
• 分子量: 234.255
• InChiKey: BNNMEAFYZHALEC-UHFFFAOYSA-N

物化性质

• 熔点：
  48-50°C
• 沸点：
  408.6±40.0 °C(Predicted)
• 密度：
  1.264±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  常规情况下不会分解，也没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  66.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090

SDS

Name:	3-Nitro-4-piperidinobenzaldehyde 95+% Material Safety Data Sheet
Synonym:
CAS:	39911-29-0

Section 1 - Chemical Product MSDS Name:3-Nitro-4-piperidinobenzaldehyde 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
39911-29-0	3-Nitro-4-piperidinobenzaldehyde	95+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 39911-29-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: orange
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 48 - 50 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C12H14N2O3
Molecular Weight: 234

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 39911-29-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Nitro-4-piperidinobenzaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 39911-29-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 39911-29-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 39911-29-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-硝基-4-(1-吡咯烷)苯甲醛 在 palladium on activated charcoal 氢气 、 溶剂黄146 作用下， 以 甲醇 、 乙酸乙酯 为溶剂， 生成 3-Amino-4-(1-piperidinyl)benzaldehyde
  参考文献：
  名称：

  Potent 2′-aminoanilide inhibitors of cFMS as potential anti-inflammatory agents

  摘要：

  A series of 2 '-aminoanilides have been identified which exhibit potent and selective inhibitory activity against the cFMS tyrosine kinase. Initial SAR studies within this series are described which examine aroyl and amino group substitutions, as well as the introduction of hydrophilic substituents on the benzene core. Compound 47 inhibits the isolated enzyme (IC50 = 0.027 mu M) and blocks CSF-1-induced proliferation of bone marrow-derived macrophages (IC50 = 0.11 mu M) and as such, serves as a lead candidate for further optimization studies. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.09.057
• 作为产物：
  描述：

  哌啶 、 4-氟-3-硝基苯甲醛 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 以100%的产率得到3-硝基-4-(1-吡咯烷)苯甲醛
  参考文献：
  名称：

  4-(二乙氨基)苯甲醛支架的扩展探索对前列腺癌醛脱氢酶活性和抗增殖活性的影响

  摘要：

  醛脱氢酶 (ALDH) 在包括前列腺癌在内的各种肿瘤类型中过度表达，被认为是治疗干预的潜在靶点。4-(二乙氨基)苯甲醛 (DEAB) 已被广泛报道为 ALDH 同种型的泛抑制剂，在这里，我们报告了 40 种 DEAB 类似物在前列腺癌细胞中的合成、ALDH 同种型选择性和细胞效力；三种类似物（14、15和16 ）显示出对 ALDH1A3 的有效抑制活性，两种类似物（18和19）显示出对 ALDH3A1 的有效抑制活性。值得注意的是，16 种类似物显示出增加的细胞毒性（IC 50= 10–200 μM) 与 DEAB (>200 μM) 相比对三种不同的前列腺癌细胞系。类似物14和18对患者来源的原发性前列腺肿瘤上皮细胞比 DEAB 更有效，作为单一药物或与多西紫杉醇联合治疗。总之，我们的研究支持使用 DEAB 作为 ALDH 抑制剂，但也揭示了密切相关的类似物，具有更高的选择性和效力。

  DOI：

  10.1021/acs.jmedchem.1c01367

文献信息

• Metal–Organic Framework‐Encapsulated CoCu Nanoparticles for the Selective Transfer Hydrogenation of Nitrobenzaldehydes: Engineering Active Armor by the Half‐Way Injection Method
  作者：Yang Li、Yu‐Nong Li、Jian‐wei Zheng、Xiao‐yun Dong、Rong‐xiu Guo、Yi‐ming Wang、Ze‐nan Hu、Yongjian Ai、Qionglin Liang、Hong‐bin Sun

  DOI：10.1002/chem.202003857

  日期：2021.1.13

  selective transfer hydrogenation of nitrobenzaldehydes into corresponding nitrobenzyl alcohols in high selectivity (99 %) and conversion (99 %) rather than nitro group reduction products. Notably, this method achieves the precise assembly of a MOF‐encapsulated composite, and the ingenious combination of MOF and nanoparticles exhibits excellent catalytic performance in the selective hydrogen transfer reaction

  由金属-有机骨架（MOF）封装的具有Fe 3 O 4核（Fe 3 O 4 @SiO 2 -NH 2 -CoCu @ UiO-66）的新型盔甲型复合材料CoCu纳米粒子已通过设计和合成。半注入法，成功地用作选择性转移氢化的有效且可回收的催化剂。在这种中途注入方法中，合成前的Fe 3 O 4 @SiO 2 -NH 2在MOF萌芽期的中途，将CoCo注入UiO-66前体溶液中。形成的MOF装甲可以起到以下作用：除CoCu纳米颗粒外，还提供大量其他催化位点，保护CoCu纳米颗粒并提高催化剂稳定性，从而促进硝基苯甲醛以高选择性（99％）和转化率选择性转移氢化为相应的硝基苄醇（ 99％）而不是硝基还原产物。值得注意的是，该方法可实现MOF封装复合材料的精确组装，并且MOF和纳米颗粒的巧妙结合在选择性氢转移反应中显示出出色的催化性能，在催化中实现了“ 1 + 1> 2”策略。
• Protecting-group-free amination of halogenated nitrobenzaldehyde with palladium catalyst
  作者：Jing Cao、Jun Xiang Feng、Yong Xiang Wu、Ya Ya Tuo

  DOI：10.1016/j.cclet.2010.03.028

  日期：2010.8

  "One-step" method for the synthesis of secondary aliphatic amine substituted nitrobenzaldehyde was developed. In the presence of Pd catalyst, halogenated nitrobenzaldehyde could be smoothly coupled with secondary aliphatic amine to give the target product in hexamethylphosphamide (HMPT) media without the protection of aldehyde groups. (C) 2010 Jing Cao. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

  开发了一种合成α-脂肪族胺取代硝基苯甲醛的“一步法”方法。在钯催化剂存在下，卤化硝基苯甲醛可顺利与二级脂肪族胺进行偶联反应，无需对醛基进行保护，在六甲基磷酰胺（HMPT）介质中即可获得目标产物。(C) 2010 �曹静。由Elsevier B.V.代表中国化学会出版。版权所有。
• [EN] ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] DERIVES D'ANABASEINE UTILES POUR LE TRAITEMENT DE MALADIES NEURODEGENERATIVES
  申请人：MEMORY PHARM CORP

  公开号：WO2004019943A1

  公开（公告）日：2004-03-11

  The compounds of the present invention are of formula (I): wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为（I）：其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。
• Heterocyclic compounds, methods for the preparation thereof, and uses thereof
  申请人：MEMORY PHARMACEUTICALS CORP.

  公开号：US20040229868A1

  公开（公告）日：2004-11-18

  The compounds of the present invention are of formula I: 1 wherein A, R 3 , R 4 is as defined herein, are useful as ligands for nicotinic receptors.

  本发明的化合物的化学式为I:1，其中A、R3、R4如本文所定义，可用作尼古丁受体的配体。
• Substituted anilinic piperidines as MCH selective antagonists
  申请人：Marzabadi R. Mohammad

  公开号：US20070043080A1

  公开（公告）日：2007-02-22

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供了一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明提供了一种由本发明化合物的治疗有效量和药学上可接受的载体组成的药物组合物。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。